Cimifugin relieves the relapse of allergic asthma via inhibiting ILC2 migration by targeting CCR9.

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Cimifugin, a primary active component of the traditional Chinese medicine Saposhnikovia divaricata (Turcz.) Schischk, is widely utilized as an anti-inflammatory remedy. Our preliminary investigations have demonstrated its efficacy in alleviating allergic asthma (AA). However, the efficacy of cimifugin against AA relapse and its underlying mechanism of action remain incompletely elucidated. AIM OF THE STUDY: The study aimed to evaluate the efficacy of cimifugin in preventing AA relapse and to elucidate its mechanism of action. MATERIALS AND METHODS: In vivo experiments were performed using the HDM-induced AA relapse mouse model, and in vitro experiments were performed by isolating lymphocytes and HEK293T cells. Vercirnon, an inhibitor of C-C motif chemokine receptor 9 (CCR9), was administered in vivo to clarify the role of group 2 innate lymphoid cell (ILC2) migration between lung and small intestine at the remission phase of AA. The effect of cimifugin on the relapse of AA was evaluated in mouse model in vivo. Cimifugin was predicted to bind directly to CCR9 by molecular docking and further confirmed by MicroScale Thermophoresis (MST). Alanine scanning and MST were used to identify the key amino acid residues of cimifugin binding to CCR9. Transwell migration experiments were performed to verify the effects of cimifugin targeting CCR9 on ILC2 migration. RESULTS: We found that administration of​ the CCR9 inhibitor vercirnon, which inhibits ILC2 migration between the lung and small intestine​ during remission, effectively alleviated AA relapse. Correspondingly, cimifugin administration at the remission phase could also alleviate the relapse of AA and inhibit the lung-small intestine migration of ILC2s. Molecular docking and MST assays showed that cimifugin directly binds to CCR9. Moreover, ARG144 and ARG323 were identified as key amino acid residues through which cimifugin binds to CCR9 to inhibit ILC2 migration. CONCLUSION: The present study revealed that cimifugin effectively inhibited the migration of ILC2s by directly targeting CCR9 to alleviate the relapse of AA, and ARG144 and ARG323 were the key amino acid residues by which cimifugin binds to CCR9. Thus, cimifugin is a novel candidate agent for relieving the relapse of AA.